Infliksimab in therapy of inflammatory bowels diseases

In last decade there were an increase in patients with inflammatory bowel disease (IBD) - Crohn's disease (CD) and ulcerative colitis (UC). To achieve remission of IBD usually was used various combinations of 5-ASK drugs, glucocorticoids and cytostatics, but positive dynamics of the patients ca...

Full description

Saved in:
Bibliographic Details
Published inĖksperimental'nai͡a︡ i klinicheskai͡a︡ gastroėnterologii͡a no. 5; p. 64
Main Authors Kniazev, O V, Lazebnik, L B, Ruchkina, I N, Tsaregorodtseva, T N, Parfenov, A I
Format Journal Article
LanguageRussian
Published Russia (Federation) 2009
Subjects
Adult
Aged
Anti-Inflammatory Agents - administration & dosage
Antibodies, Monoclonal - administration & dosage
Colitis, Ulcerative - blood
Colitis, Ulcerative - drug therapy
Crohn Disease - blood
Crohn Disease - drug therapy
Female
Humans
Infliximab
Male
Middle Aged
Remission Induction
Online AccessGet more information

Cover

More Information
Summary:In last decade there were an increase in patients with inflammatory bowel disease (IBD) - Crohn's disease (CD) and ulcerative colitis (UC). To achieve remission of IBD usually was used various combinations of 5-ASK drugs, glucocorticoids and cytostatics, but positive dynamics of the patients cannot achieve. In this regard some prospects assigned to infliksimabom therapy. You can find results of Remikeyd therapy in patients with Crohn's disease and ulcerative colitis. We showed that all cases achieved positive dynamics within the IBD, which allowed him to recommend as an effective tool in the form of monotherapy for one year.
ISSN:1682-8658